Navigation Links
Irritable Bowel Syndrome Pronounced With Low Birth Weight

Irritable Bowel Syndrome (IBS) and low birth weight seems to have a connection, suggests a new academic insight. Norwegian researchers have unearthed the link, to // indicate that babies who weigh less than 5.5lbs at birth, carry a greater chance of coming down with Irritable Bowel Syndrome , in comparison to heavier babies. The findings of this study have been documented in the Journal "Gut".

IBS is annoying, leaving its victims with discomfort - abdominal pain, diarrhea and constipation. This is probably due to an immature digestive system, linked to low birth weight that exacerbates the risk of IBS.

To comprehend the link, 3,334 pairs of identical and fraternal twins born between 1967 and 1979, were inducted as study subjects. The data of birth weight and the condition of the subjects with relation to IBS development was noted.

The study revealed that the nearly one in 20 portrayed acute symptoms of Irritable Bowel Syndrome, with women showing a greater propensity to suffer IBS. Researchers were quick to enable risk factors, which clearly showed that babies weighing less than 5.5lbs carried an elevated risk of suffering IBS. Birth weight, lower than 3.3lbs carried a much higher risk, equated at 2.5 times higher than babies weighing below 5.5lbs.

Lead researcher Dr. May-Bente Bengston, of the University of Oslo, said "It could be because the gut system has restricted development in smaller babies. This could mean the bowel is affected, causing IBS symptoms, but we really cannot be sure."
SAV
'"/>




Page: 1

Related medicine news :

1. Irritable bowel syndrome associated with food intake, confirms blood test
2. Restricted Fetal Growth Increases Risk of Irritable Bowel Syndrome
3. Woman Says Irritable Bowel Drove Her to Shoplifting
4. Bowel diseases linked to bug in milk
5. Hope For Patients With Inflammatory Bowel Disease
6. Cannabinoids - Antidepressant And Inflammatory Bowel Disease Treatment
7. Eating Red and Processed Meat may cause Bowel cancer
8. Just Had Bowel Surgery? Chew Gum For A Speedy Recovery
9. Delay In Life-Saving Bowel Cancer Screening Programme In UK
10. National Bowel Cancer Screening Programme Lauded
11. Bowel Cancer Drug Campaigner Dies After Surgery
Post Your Comments:
(Date:12/4/2009)Working with mice, scientists at Johns Hopkins publishing in the December issue of Neoplasia have shown that a protein made by a gene called "Twist" may be the proverbial red flag that can accuratel
(Date:12/4/2009)More than 15 million Americans are recruited annually to participate in clinical trials according to the Alliance for Human Research Protection (AHRP), and most will be compensated for their participa
(Date:12/4/2009)Dental tourism is a phenomenon that was started by people that were looking for an alternative to the high price of dental work in the US, Canada, and other countries. In their search for lower priced
(Date:12/4/2009)Increasing exercise, water and fruit consumption leads to success, study finds , , FRIDAY, Dec. 4 (HealthDay News) -- Increased exercise, reduced soda consumption and self-weighing are among
(Date:12/4/2009)BOSTON, Dec. 4 Substantial progress has been made over the last 15 years in the healthcare community,s ability to diagnose and treat epilepsy and its complications. Yet this progress in epilepsy man
Breaking Medicine News(10 mins):Health News:Potential new 'twist' in breast cancer detection 2Health News:Potential new 'twist' in breast cancer detection 3Health News:Human guinea pigs wary of high-paying medical trials 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 3Health News:Teens Lose More Weight Using Healthy Strategies 2Health News:Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care 2Health News:Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care 3Health News:Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care 4
...t Washington University School of Medicine in St. ...pic worms to survive in a low-oxygen, or hypoxic, ...e implications for conditions such as stroke, hear...the Jan. 30 issue of the journal Science . , "In...
... Today, Jiffy Lube® service centers in S...entral Coast of California, the Spokane and Tri-Ci...nounce their participation in the second year of t... the nation,s number one killer of women and men, ...
... illness in cattle months before symptoms appear, ...thDay News) -- A simple, inexpensive DNA blood tes...cattle months before they show any clinical signs ...brain samples from dead animals. The ability to te...
... (BRONX, NY) Men who develop prostate cancer face...f they carry a so-called breast cancer gene mutati... Medicine of Yeshiva University report in today,s ... The study, involving 979 men with prostate cancer...
... Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) c...D filing with the Securities and Exchange Commissi...filiated funds announcing their intent to nominate... this action. , , Amylin,s Corporate Governance C...
...nly used to improve physical function, decrease sy...ow back or neck pain. Numerous randomized trials a...s practice, and studies suggest that individually ...on, including who is prescribing it, who is gettin...
Other Medicine News:Health News:Worm provides clues about preventing damage caused by low-oxygen during stroke, heart attack 2Health News:Worm provides clues about preventing damage caused by low-oxygen during stroke, heart attack 3Health News:Jiffy Lube Service Centers Kick-off Year Two Of Maintenance Partners For Life Campaign To Benefit American Heart Association 2Health News:Jiffy Lube Service Centers Kick-off Year Two Of Maintenance Partners For Life Campaign To Benefit American Heart Association 3Health News:Jiffy Lube Service Centers Kick-off Year Two Of Maintenance Partners For Life Campaign To Benefit American Heart Association 4Health News:Blood Test for 'Mad Cow' Disease May Be Near 2Health News:Gene mutations increase risk for aggressive prostate cancer 2Health News:Gene mutations increase risk for aggressive prostate cancer 3Health News:Exercise underutilized for chronic back and neck pain 2Health News:Exercise underutilized for chronic back and neck pain 3
(Date:12/4/2009)WILMINGTON, Del., Dec. 4 AstraZeneca (NYSE: AZN ) today announced that the US Food and Drug Administration (FDA) has approved once-daily SEROQUEL XR® (quetiapine fumarate) Extended Release Tab
(Date:12/3/2009)NEW YORK, Dec. 3 Guidepoint Global, LLC , a leading primary research firm, today announced the launch of their Sleep Apnea Tracker, a monthly longitudinal data release that monitors and projects tre
(Date:12/3/2009)ALISO VIEJO, Calif. and STATE COLLEGE, Pa., Dec. 3 Ambry Genetics and SoftGenetics today announced the signing of an agreement to provide extended bioinformatics genomics services using SoftGenetics,
Breaking Medicine Technology:US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 2US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 5US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 6US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 7US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 8US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 9Leading Primary Research Firm Guidepoint Global Announces Launch of Sleep Apnea Tracker 2Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 2Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 3Thomson Reuters Partners With Sagient Research 13050 1Thomson Reuters Partners With Sagient Research 13050 2NEA Portfolio Companies Selected as Zero2IPO Venture 50 and China Entrepreneur Rising Stars Honorees 51801 1NEA Portfolio Companies Selected as Zero2IPO Venture 50 and China Entrepreneur Rising Stars Honorees 51801 2NEA Portfolio Companies Selected as Zero2IPO Venture 50 and China Entrepreneur Rising Stars Honorees 51801 3Number of Underweight Kids in U S Continues to Shrink 51798 1
...KERB Demonstrates Activity in Combination with Oth...ss A Range of Breast Cancer Settings, - First Pha...R2 and VEGF, pathways with two oral, small molecul...ib) demonstrates activity in first-line HER2 (ErbB...er(1) - Phase II results combining TYKERB and AVA...
...ICAGO, May 31 Millennium Pharmaceuticals, The Tak...tion of results from three,clinical trials of VELC...complete remission(1) (CR) rates in patients with ...f the best predictors of long-term survival. These... at the American Society,of Clinical Oncology (ASC...
Other Medicine Technology:New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens 2New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens 3New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens 4New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens 5New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens 6New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens 7New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens 8New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens 9New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens 10Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 2Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 3Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 4Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 5Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 6Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 7
Bechert Nucleus Rotator
Lambert Membrane Hook-Pick - Right
Olk Angled Retinal Pick - 150 Degree
Sweeney Manipulator Cracker
Medicine Products: